Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : scours supply chain for more vaccine doses for Thailand, SE Asia

07/24/2021 | 02:54am EDT
COVID-19 vaccinations in Bangkok

BANGKOK (Reuters) - AstraZeneca Plc is "scouring" its global supply chain to try and boost COVID-19 vaccine supplies to Thailand and Southeast Asia, its representative for the country said on Saturday, amidst speculations of local production shortfalls.

The comments come after leaked letters https://www.reuters.com/business/healthcare-pharmaceuticals/leaked-letters-show-astrazeneca-vaccine-commitment-not-thailand-claimed-2021-07-19 showed last week that the drugmaker had offered to supply 5-6 million vaccine doses a month to Thailand, contradicting assertions by Thai officials that the government is owed 10 million a month and 61 million doses by end-2021.

AstraZeneca is "scouring the 20+ supply chains in our worldwide manufacturing network to find additional vaccines for Southeast Asia, including Thailand", James Teague, managing director of AstraZeneca Thailand, said in a statement.

"We are hopeful of importing additional doses in the months ahead," he added.

The drugmaker had previously said vaccine doses for Thailand and Southeast Asia would come from a plant of its Thai partner Siam Bioscience, owned by Thailand's king and a first-time vaccine maker.

Pressure has been mounting on the company after Thailand said it was considering imposing limits https://www.reuters.com/world/asia-pacific/thailand-considering-regulating-volume-astrazeneca-vaccine-exports-health-2021-07-14 on exports of locally manufactured AstraZeneca COVID-19 vaccines to shore up domestic supplies, a move that could hit its neighbours, some of which are battling similar or more severe COVID-19 crises.

Siam Bioscience has not commented on reports of production shortfalls or delivery timelines.

Teague said AstraZeneca has delivered 9 million does so far to Thailand and will deliver 2.3 million more next week.

Thailand has fully inoculated just 5.56% of its population of more than 66 million so far, while 18.62% have received at least one dose, government data shows.

(Reporting by Patpicha Tanakasempipat; Editing by Kay Johnson and Himani Sarkar)

© Reuters 2021
All news about ASTRAZENECA PLC
12:12pASTRAZENECA : Enhertu demonstrated clinically meaningful and durable response in..
12:06pASTRAZENECA : ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically..
10:50aAstraZeneca Sees Positive Results for Enhertu Trial
10:09aLATEST : FDA panel to offer recommendations on booster shots
09:18aASTRAZENECA : EMA Fails To Find Link Between Blood Clots, AstraZeneca's Vaccine
08:23aASTRAZENECA : Says Imfinzi-Oleclumab Combination Improved Clinical Outcomes for ..
08:06aJOHNSON & JOHNSON : GSA Director Lauded for Luring More People to Get Covid-19 V..
07:31aASTRAZENECA : EU unsure if women face higher risk of clots from AstraZeneca shot
07:31aASTRAZENECA : IMFINZI Combined With Novel Immunotherapies Improved Clinical Outc..
07:11aASTRAZENECA : Buy rating from Morgan Stanley
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 214 M - -
Net income 2021 4 990 M - -
Net Debt 2021 24 654 M - -
P/E ratio 2021 31,5x
Yield 2021 2,51%
Capitalization 172 B 172 B -
EV / Sales 2021 5,59x
EV / Sales 2022 4,52x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 112,31 $
Average target price 136,08 $
Spread / Average Target 21,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC11.16%173 735
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887